Dear colleagues and friends,

It is a great pleasure to welcome you to the CNS Metastasis Meeting in Brussels, jointly organized under the auspices of EANO and EORTC. Brain metastases represent one of the most pressing challenges in contemporary oncology. Once considered a late and largely untreatable complication of systemic cancer, they are now recognized as a biologically distinct and increasingly actionable disease. Rapid advances across multiple disciplines—from cancer biology and neuroscience to immunology and clinical research—are reshaping our understanding and opening new therapeutic opportunities. At the same time, these developments demand closer integration between preclinical discovery, translational research, and clinical practice.

This meeting has evolved from the highly successful Brain Mets meeting held since 2011 and marks a new phase in the evolution of the CNS Metastasis Conference. With the joint leadership of EANO and EORTC, our aim is to establish a truly international, multidisciplinary forum that brings together leading experts across the full spectrum of the field. The program has been carefully designed to reflect this ambition, highlighting cutting-edge science alongside clinical innovation, and fostering dialogue between laboratory researchers, clinicians, and trialists.

We believe that Europe is uniquely positioned to lead in this space through strong collaborative networks, scientific excellence, and a growing commitment to addressing central nervous system involvement in cancer. By uniting these strengths, this meeting seeks not only to showcase the latest advances, but also to define future directions and accelerate progress for patients.

Equally important, we are committed to creating an environment that supports the next generation of investigators. Through the inclusion of selected abstracts, poster sessions, and opportunities for interaction, we hope to encourage new ideas, collaborations, and long-term engagement within the community. We are confident that this meeting will become a reference point for the field of CNS metastasis, complementing and strengthening global efforts. Above all, we hope it will serve as a catalyst for innovation and collaboration, ultimately improving outcomes for patients affected by these challenging diseases.

We thank you for your participation and look forward to a stimulating and productive meeting.